This analysis included 115 patients with CML-CP without T315I who were enrolled in the study (May 2014–October 2019) and received asciminib monotherapy (Fig. 1A, Supplementary Table S1 and Supplementary Fig. S2). The gene discussed is CP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.